Antidepressant-like Properties of Melatonin and Atorvastatin Combination following the Restraint Stress in Mice : A Study of Oxidative Stress Factors
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Antidepressant properties of melatonin and atorvastatin have been reported by clinical and experimental studies. Since both melatonin and atorvastatin possess antioxidant properties and considering the involvement of oxidative stress factors in depression, the aim of the present investigation was to study the possible role of oxidative stress factors in the antidepressant- like effect of melatonin and atorvastatin combination in mice forced swimming test.
METHODS: Following the induction of restraint stress, mice were randomly divided into eight groups including the non-stressed and stressed vehicle-treated groups, melatonin- and atorvastatintreated groups, a combination of melatonin and atorvastatin-treated group, and fluoxetineadministrated group. The open field test (OFT) and forced swimming test (FST) were carried out, and the hippocampus and prefrontal cortex were removed for the measurement of oxidative stress factors.
RESULTS: Induction of restraint stress increased the immobility time in FST, and melatonin (10 mg/kg) significantly reduced it. Atorvastatin at both doses of 1 and 10 mg/kg could not alter the immobility time, significantly. Co-administration of melatonin and atorvastatin (10 mg/kg) exerted a significant antidepressant-like response and decreased the immobility time compared with melatonin or atorvastatin (10 mg/kg), alone. Induction of restraint stress elevated the malondialdehyde (MDA) levels in mice's hippocampus, while pretreatment of animals with atorvastatin (10 mg/kg) could reverse it. The co-administration of melatonin and atorvastatin (10 mg/kg) increased the cortical superoxide dismutase (SOD) activity compared with atorvastatin alone, but could not alter the catalase (CAT) activity.
CONCLUSION: It is concluded that atorvastatin might augment the antidepressant-like properties of melatonin in FST.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Central nervous system agents in medicinal chemistry - 23(2023), 1 vom: 18., Seite 32-39 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nikoui, Vahid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
A0JWA85V8F |
|---|
| Anmerkungen: |
Date Completed 04.07.2023 Date Revised 04.07.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871524923666221121111501 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349247196 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349247196 | ||
| 003 | DE-627 | ||
| 005 | 20231226042150.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871524923666221121111501 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349247196 | ||
| 035 | |a (NLM)36411564 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nikoui, Vahid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antidepressant-like Properties of Melatonin and Atorvastatin Combination following the Restraint Stress in Mice |b A Study of Oxidative Stress Factors |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.07.2023 | ||
| 500 | |a Date Revised 04.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Antidepressant properties of melatonin and atorvastatin have been reported by clinical and experimental studies. Since both melatonin and atorvastatin possess antioxidant properties and considering the involvement of oxidative stress factors in depression, the aim of the present investigation was to study the possible role of oxidative stress factors in the antidepressant- like effect of melatonin and atorvastatin combination in mice forced swimming test | ||
| 520 | |a METHODS: Following the induction of restraint stress, mice were randomly divided into eight groups including the non-stressed and stressed vehicle-treated groups, melatonin- and atorvastatintreated groups, a combination of melatonin and atorvastatin-treated group, and fluoxetineadministrated group. The open field test (OFT) and forced swimming test (FST) were carried out, and the hippocampus and prefrontal cortex were removed for the measurement of oxidative stress factors | ||
| 520 | |a RESULTS: Induction of restraint stress increased the immobility time in FST, and melatonin (10 mg/kg) significantly reduced it. Atorvastatin at both doses of 1 and 10 mg/kg could not alter the immobility time, significantly. Co-administration of melatonin and atorvastatin (10 mg/kg) exerted a significant antidepressant-like response and decreased the immobility time compared with melatonin or atorvastatin (10 mg/kg), alone. Induction of restraint stress elevated the malondialdehyde (MDA) levels in mice's hippocampus, while pretreatment of animals with atorvastatin (10 mg/kg) could reverse it. The co-administration of melatonin and atorvastatin (10 mg/kg) increased the cortical superoxide dismutase (SOD) activity compared with atorvastatin alone, but could not alter the catalase (CAT) activity | ||
| 520 | |a CONCLUSION: It is concluded that atorvastatin might augment the antidepressant-like properties of melatonin in FST | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Depression | |
| 650 | 4 | |a atorvastatin | |
| 650 | 4 | |a forced swimming test | |
| 650 | 4 | |a melatonin | |
| 650 | 4 | |a mice | |
| 650 | 4 | |a pharmacology | |
| 650 | 7 | |a Atorvastatin |2 NLM | |
| 650 | 7 | |a A0JWA85V8F |2 NLM | |
| 650 | 7 | |a Melatonin |2 NLM | |
| 650 | 7 | |a JL5DK93RCL |2 NLM | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 700 | 1 | |a Hosseinzadeh, Azam |e verfasserin |4 aut | |
| 700 | 1 | |a Khotab, Solmaz Javadi |e verfasserin |4 aut | |
| 700 | 1 | |a Mousavi, Seyyedeh Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Abolmaali, Meysam |e verfasserin |4 aut | |
| 700 | 1 | |a Mehrzadi, Saeed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Central nervous system agents in medicinal chemistry |d 2008 |g 23(2023), 1 vom: 18., Seite 32-39 |w (DE-627)NLM185149960 |x 1875-6166 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:18 |g pages:32-39 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871524923666221121111501 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 18 |h 32-39 | ||